🚀 VC round data is live in beta, check it out!
Roivant Sciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Roivant Sciences and similar public comparables like Revolution Medicines, Incyte, Royalty Pharma, Moderna and more.
Roivant Sciences Overview
About Roivant Sciences
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Founded
2014
HQ
Employees
750
Website
Sectors
Financials (LTM)
EV
$16B
Roivant Sciences Financials
Roivant Sciences reported last 12-month revenue of $10M and negative EBITDA of ($1B).
In the same LTM period, Roivant Sciences generated $9M in gross profit, ($1B) in EBITDA losses, and had net loss of ($805M).
Revenue (LTM)
Roivant Sciences P&L
In the most recent fiscal year, Roivant Sciences reported revenue of $29M and EBITDA of ($938M).
Roivant Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $10M | XXX | $29M | XXX | XXX | XXX |
| Gross Profit | $9M | XXX | $28M | XXX | XXX | XXX |
| Gross Margin | 86% | XXX | 97% | XXX | XXX | XXX |
| EBITDA | ($1B) | XXX | ($938M) | XXX | XXX | XXX |
| EBITDA Margin | (11637%) | XXX | (3227%) | XXX | XXX | XXX |
| EBIT Margin | (10521%) | XXX | (3148%) | XXX | XXX | XXX |
| Net Profit | ($805M) | XXX | ($172M) | XXX | XXX | XXX |
| Net Margin | (8063%) | XXX | (592%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Roivant Sciences Stock Performance
Roivant Sciences has current market cap of $20B, and enterprise value of $16B.
Market Cap Evolution
Roivant Sciences' stock price is $28.08.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $16B | $20B | 0.0% | XXX | XXX | XXX | $-0.24 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialRoivant Sciences Valuation Multiples
Roivant Sciences trades at 1569.9x EV/Revenue multiple, and (13.5x) EV/EBITDA.
EV / Revenue (LTM)
Roivant Sciences Financial Valuation Multiples
As of March 21, 2026, Roivant Sciences has market cap of $20B and EV of $16B.
Equity research analysts estimate Roivant Sciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Roivant Sciences has a P/E ratio of (25.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $20B | XXX | $20B | XXX | XXX | XXX |
| EV (current) | $16B | XXX | $16B | XXX | XXX | XXX |
| EV/Revenue | 1569.9x | XXX | 539.6x | XXX | XXX | XXX |
| EV/EBITDA | (13.5x) | XXX | (16.7x) | XXX | XXX | XXX |
| EV/EBIT | (14.9x) | XXX | (17.1x) | XXX | XXX | XXX |
| EV/Gross Profit | 1820.9x | XXX | 557.0x | XXX | XXX | XXX |
| P/E | (25.0x) | XXX | (116.9x) | XXX | XXX | XXX |
| EV/FCF | (18.9x) | XXX | (18.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Roivant Sciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Roivant Sciences Margins & Growth Rates
Roivant Sciences' revenue in the last 12 month grew by 338%.
Roivant Sciences' revenue per employee in the last FY averaged $0.0M.
Roivant Sciences' rule of 40 is (11300%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Roivant Sciences' rule of X is (10793%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Roivant Sciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 338% | XXX | (68%) | XXX | XXX | XXX |
| EBITDA Margin | (11637%) | XXX | (3227%) | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | 25% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (11300%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (10793%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4508% | XXX | 2036% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 6311% | XXX | 1895% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 3930% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Roivant Sciences Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Revolution Medicines | XXX | XXX | XXX | XXX | XXX | XXX |
| Incyte | XXX | XXX | XXX | XXX | XXX | XXX |
| Royalty Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Moderna | XXX | XXX | XXX | XXX | XXX | XXX |
| Shionogi | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Roivant Sciences M&A Activity
Roivant Sciences acquired XXX companies to date.
Last acquisition by Roivant Sciences was on XXXXXXXX, XXXXX. Roivant Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Roivant Sciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialRoivant Sciences Investment Activity
Roivant Sciences invested in XXX companies to date.
Roivant Sciences made its latest investment on XXXXXXXX, XXXXX. Roivant Sciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Roivant Sciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Roivant Sciences
| When was Roivant Sciences founded? | Roivant Sciences was founded in 2014. |
| Where is Roivant Sciences headquartered? | Roivant Sciences is headquartered in United Kingdom. |
| How many employees does Roivant Sciences have? | As of today, Roivant Sciences has over 750 employees. |
| Who is the CEO of Roivant Sciences? | Roivant Sciences' CEO is Eric Venker. |
| Is Roivant Sciences publicly listed? | Yes, Roivant Sciences is a public company listed on Nasdaq. |
| What is the stock symbol of Roivant Sciences? | Roivant Sciences trades under ROIV ticker. |
| When did Roivant Sciences go public? | Roivant Sciences went public in 2021. |
| Who are competitors of Roivant Sciences? | Roivant Sciences main competitors are Revolution Medicines, Incyte, Royalty Pharma, Moderna. |
| What is the current market cap of Roivant Sciences? | Roivant Sciences' current market cap is $20B. |
| What is the current revenue of Roivant Sciences? | Roivant Sciences' last 12 months revenue is $10M. |
| What is the current revenue growth of Roivant Sciences? | Roivant Sciences revenue growth (NTM/LTM) is 338%. |
| What is the current EV/Revenue multiple of Roivant Sciences? | Current revenue multiple of Roivant Sciences is 1569.9x. |
| Is Roivant Sciences profitable? | No, Roivant Sciences is not profitable. |
| What is the current EBITDA of Roivant Sciences? | Roivant Sciences has negative EBITDA and is not profitable. |
| What is Roivant Sciences' EBITDA margin? | Roivant Sciences' last 12 months EBITDA margin is (11637%). |
| What is the current EV/EBITDA multiple of Roivant Sciences? | Current EBITDA multiple of Roivant Sciences is (13.5x). |
| What is the current FCF of Roivant Sciences? | Roivant Sciences' last 12 months FCF is ($829M). |
| What is Roivant Sciences' FCF margin? | Roivant Sciences' last 12 months FCF margin is (8302%). |
| What is the current EV/FCF multiple of Roivant Sciences? | Current FCF multiple of Roivant Sciences is (18.9x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.